MedTrace Logo

SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes

NCT04816084 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 389

Last updated 2021-03-25

No results posted yet for this study

Summary

This study was designed to determine, in a screening situation within the framework of university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the staff of the University of Reims Champagne-Ardenne. The serological tests chosen will allow systematic detection of anti-SARS-CoV-2 IgM and anti-SARS-Cov-2 IgG to assess the moment of potential contamination prior to resumption of occupational activity.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Anti-SARS-CoV2 Serology

Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®) Other: Questionnaire Data concerning personal exposure factors are collected in a questionnaire: * Socio-demographic factors: sex, age, * known risk-factor for Covid-19 * Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination * Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays

Sponsors & Collaborators

  • Université de Reims Champagne-Ardenne

    lead OTHER

Principal Investigators

  • Delphine GIUSTI, MCU-PH · Université de Reims CHampahne-Ardenne - CHU de Reims

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-05
Primary Completion
2020-12-01
Completion
2021-03-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04816084 on ClinicalTrials.gov